Mental health means new neurons?

A gene strongly associated with schizophrenia and other neuropsychiatric disorders regulates the birth of new neurons in the adult brain, according to new research. linkurl:The study,;http://www.cell.com/fulltext/S0092-8674(09)00021-X published in Cell this week, supports a controversial theory linking diseases such as schizophrenia and depression to neurogenesis and provides new targets for the treatment of psychiatric conditions. Image: flicker/linkurl:Staurland;http://www.flickr.com/photos/

Written byAlla Katsnelson
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share
A gene strongly associated with schizophrenia and other neuropsychiatric disorders regulates the birth of new neurons in the adult brain, according to new research. linkurl:The study,;http://www.cell.com/fulltext/S0092-8674(09)00021-X published in Cell this week, supports a controversial theory linking diseases such as schizophrenia and depression to neurogenesis and provides new targets for the treatment of psychiatric conditions.
Image: flicker/linkurl:Staurland;http://www.flickr.com/photos/staurland3
"This is the first time anybody has ever shown that this protein [coded by the gene] directly regulates the number of neural progenitors," said linkurl:Li-Huei Tsai,;http://web.mit.edu/picower/faculty/tsai.html main author and neuroscientist at the Picower Institute of Learning and Memory at the Massachusetts Institute of Technology. Previous studies have linked schizophrenia to disturbances in neurogenesis in a brain region called the hippocampus and suggested that anti-depressant medications such as Prozac work by stimulating hippocampal neurogenesis. The new findings link the gene, DISC1, to a well-studied signaling pathway that controls neurogenesis and the development of the nervous system. "It really fits in with a lot of background information to suggest that hippocampal neurogenesis in particular is potentially a process which is going wrong in psychiatric illness," said linkurl:Ben Pickard,;http://www.schizophreniaforum.org/com/res/detail.asp?id={98699AC1-C5A8-4B00-B834-CE4937812B40} a medical geneticist at the University of Edinburgh who was not involved in the study. Researchers first made the link between DISC1 and psychiatric disorders linkurl:in 2001;http://www.ncbi.nlm.nih.gov/pubmed/11443544 -- a large Scottish family with a high incidence of schizophrenia and bipolar disorder displayed a specific translocation in the gene's sequence. Since then, Tsai and others have linked other mutations in the gene to psychiatric disorders. There have been suggestions that DISC1 is involved in linkurl:early cortical development;http://www.ncbi.nlm.nih.gov/pubmed/16299498 and linkurl:integrating;http://www.ncbi.nlm.nih.gov/pubmed/17825401 newly produced neurons in the adult brain, but "because there were no sequence matches in the database," explained Pickard, "it was very hard to figure out what it does." Tsai, who is a Howard Hughes Medical Institute investigator, and her colleagues showed that the DISC1 protein interacts with a protein called GSK3-beta, muffling its effect. The role of GSK3-beta is to inhibit the function of the protein beta-catenin, which promotes stem cell proliferation. In essence, the job of DISC1 is to inhibit the inhibition of neurogenesis. If a mutation in the gene is blocking the protein from doing its job, GSK3-beta is left exerting its inhibitory effect on neuronal growth, potentially causing different psychiatric illnesses. When the researchers silenced DISC1 in the hippocampus of adult mice using RNA interference, the mice showed symptoms associated with schizophrenia and depression. Interestingly, Pickard and Tsai noted that GSK3-beta is the molecular target of lithium, the most effective treatment available for bipolar disorder. Although the compound has been used for decades, how it works is largely unknown. Tsai's findings suggest that lithium's mechanism may involve stimulating neurogenesis. "One of the most exciting aspects of the study is the parallel between this one function and lithium," said Tsai. That knowledge may also provide a genetic means of predicting which patients will respond to lithium. Indeed, the clear link the study makes between the genetics and the pathophysiology is "giving us clues as to why the medications might work in some people and not in others," said linkurl:David Porteous,;http://www.cip.ed.ac.uk/members/not_HRB/porteous/index.htm a molecular geneticist also at the University of Edinburgh who was not involved in the present work, and who coauthored the original DISC1 family study. "In that regard, it's not just a very good piece of science; it's also giving us a roadmap to what we should be doing next." That will involve working out the fine details of how DISC1 and GSK3-beta work together, and how other molecules are involved, Porteous said -- a project which Tsai's lab is now working on. Three years ago, Porteous, Pickard and others implicated DISC1 in linkurl:another pathway;http://www.ncbi.nlm.nih.gov/pubmed/16293762 central to brain development. How the two interact may yield further clues to the molecular underpinnings of psychiatric illnesses. "We're starting to develop a kind of genetic network around the DISC1 pathway," he said, which points to "targets for intervention in a much more rational fashion than what's been possible."
**__Related stories:__***linkurl:Schizophrenia (special supplement);http://www.the-scientist.com/supplement/2007-12-1/
[December 2007]*linkurl:Growing a new antidepressant;http://www.the-scientist.com/2007/4/1/40/1/
[April 2007]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies